Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m(2) for definitive radiochemotherapy of locally advanced head-and-neck cancers.

Rades D, Seidl D, Janssen S, Bajrovic A, Karner K, Strojan P, Schild SE.

BMC Cancer. 2016 Jul 8;16:437. doi: 10.1186/s12885-016-2478-8.

2.

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.

Fayette J, Molin Y, Lavergne E, Montbarbon X, Racadot S, Poupart M, Ramade A, Zrounba P, Ceruse P, Pommier P.

Drug Des Devel Ther. 2015 Nov 26;9:6203-10. doi: 10.2147/DDDT.S81488. eCollection 2015.

3.

Depletion of the cisplatin targeted HMGB-box factor UBF selectively induces p53-independent apoptotic death in transformed cells.

Hamdane N, Herdman C, Mars JC, Stefanovsky V, Tremblay MG, Moss T.

Oncotarget. 2015 Sep 29;6(29):27519-36. doi: 10.18632/oncotarget.4823.

4.

Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma.

Kang MH, Kang JH, Song HN, Jeong BK, Chai GY, Kang K, Woo SH, Park JJ, Kim JP.

Cancer Res Treat. 2015 Jul;47(3):441-7. doi: 10.4143/crt.2013.219. Epub 2014 Dec 2.

5.

Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma.

Tao CJ, Lin L, Zhou GQ, Tang LL, Chen L, Mao YP, Zeng MS, Kang TB, Jia WH, Shao JY, Mai HQ, Lin AH, Ma J, Sun Y.

PLoS One. 2014 Oct 16;9(10):e110765. doi: 10.1371/journal.pone.0110765. eCollection 2014.

6.

Postoperative concomitant chemoradiotherapy improved treatment outcomes of patients with oral cavity cancer with multiple-node metastases but no other major risk factors.

Fan KH, Lin CY, Kang CJ, Lee LY, Huang SF, Liao CT, Chen IH, Ng SH, Wang HM, Chang JT.

PLoS One. 2014 Feb 24;9(2):e86922. doi: 10.1371/journal.pone.0086922. eCollection 2014.

7.

Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma.

Yi J, Huang X, Gao L, Luo J, Zhang S, Wang K, Qu Y, Xiao J, Xu G.

Radiat Oncol. 2014 Feb 18;9:56. doi: 10.1186/1748-717X-9-56.

8.

The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity.

Tsan DL, Lin CY, Kang CJ, Huang SF, Fan KH, Liao CT, Chen IH, Lee LY, Wang HM, Chang JT.

Radiat Oncol. 2012 Dec 18;7:215. doi: 10.1186/1748-717X-7-215.

9.
10.

Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382).

Quon H, Leong T, Haselow R, Leipzig B, Cooper J, Forastiere A.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):719-25. doi: 10.1016/j.ijrobp.2010.06.038. Epub 2010 Oct 1.

11.

Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.

Gupta T, Agarwal JP, Ghosh-Laskar S, Parikh PM, D'Cruz AK, Dinshaw KA.

Head Neck Oncol. 2009 Jun 15;1:17. doi: 10.1186/1758-3284-1-17.

Items per page

Supplemental Content

Write to the Help Desk